- Home
- STEC vs NXTC Comparison
STEC vs NXTC Comparison
Compare STEC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- NXTC
- Stock Information
- Founded
- STEC 2006
- NXTC 2015
- Country
- STEC China
- NXTC United States
- Employees
- STEC N/A
- NXTC N/A
- Industry
- STEC
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- NXTC Health Care
- Exchange
- STEC NYSE
- NXTC Nasdaq
- Market Cap
- STEC 21.0M
- NXTC 23.0M
- IPO Year
- STEC 2021
- NXTC 2019
- Fundamental
- Price
- STEC $0.77
- NXTC $0.80
- Analyst Decision
- STEC
- NXTC Strong Buy
- Analyst Count
- STEC 0
- NXTC 2
- Target Price
- STEC N/A
- NXTC $4.00
- AVG Volume (30 Days)
- STEC 303.5K
- NXTC 199.8K
- Earning Date
- STEC 02-04-2025
- NXTC 03-20-2025
- Dividend Yield
- STEC N/A
- NXTC N/A
- EPS Growth
- STEC N/A
- NXTC N/A
- EPS
- STEC N/A
- NXTC N/A
- Revenue
- STEC $260,474,693.00
- NXTC N/A
- Revenue This Year
- STEC $9.76
- NXTC N/A
- Revenue Next Year
- STEC $15.85
- NXTC N/A
- P/E Ratio
- STEC N/A
- NXTC N/A
- Revenue Growth
- STEC N/A
- NXTC N/A
- 52 Week Low
- STEC $0.20
- NXTC $0.76
- 52 Week High
- STEC $3.25
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- STEC 47.18
- NXTC 38.00
- Support Level
- STEC $0.69
- NXTC $0.76
- Resistance Level
- STEC $0.79
- NXTC $0.83
- Average True Range (ATR)
- STEC 0.12
- NXTC 0.06
- MACD
- STEC -0.00
- NXTC 0.01
- Stochastic Oscillator
- STEC 14.30
- NXTC 18.72
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.